Formerly known as COL-3, Incyclinide is a chemically modified tetracycline, modified to retain non-antibiotic properties that may make them effective in treating diseases involving inflammation and/or destruction of the body’s connective tissues.
CollaGenex have announced that the National Institutes of Health (“NIH”) has awarded a grant of approximately $962,000 for additional research into the potent anti-inflammatory effects of incyclinide.
The grant will be paid over two years and will support CollaGenex’s manufacturing and formulation development of incyclinide as well as preclinical studies. This will further enable researchers to “conduct additional studies that should advance the Company’s understanding of incyclinide’s potent anti-inflammatory properties”.
“In clinical studies of patients with Kaposi’s sarcoma and rosacea, we saw dramatic improvements in these inflammatory disorders in patients administered incyclinide. This NIH grant will help us better understand incyclinide’s mechanisms of action and its potential to treat acute inflammatory conditions.”
Related Articles:
- COL-3 new tetracycline derivative being studied
- Incyclinide phase 2 for acne
- low dose doxycycline hyclate (SDD)
- Subantimicrobial Dose Doxycycline for Acne and Rosacea
- Periostat (doxycycline) goes generic, get ready for Oracea
- incyclinide targets conditions other than rosacea
- how do tetracyclines help rosacea ?
- incyclinide fails for rosacea, acne still possible
Hi,
What ever happened to all of the grant money that the National Institute of Health donated to Collagenex (I think it was around $1,000,000) to help develop Incyclinide? I heard that the drug failed for long-term Rosacea treatment and they were stopping production of the drug for Acne clinical trials. So now, where is that money, lining some CEO’s pocket at that company?
Those of us who suffer from Rosacea get awfully tired of seeing one shining light after another snuffed out for a possible cure for this disease.
Jasmine
March 2008